Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Biocon Receives US FDA Approval for Breast Cancer Biosimilar Pebrilzo

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Biocon Receives US FDA Approval for Breast Cancer Biosimilar Pebrilzo

Analysed 16 Nov 2026·4 sources analysed·New Delhi, India·Business
Biocon Receives US FDA Approval for Breast Cancer Biosimilar PebrilzoPreviousNext

Biocon Limited has received US FDA approval for Pebrilzo (pertuzumab-qcay), its fifth oncology biosimilar, used to treat HER2-positive breast cancer by blocking HER2 receptors. The drug is indicated for use with trastuzumab and chemotherapy in early-stage and metastatic cases. Biocon has also secured a global settlement and license agreement with Genentech, allowing a US launch in the third quarter of 2028. The approval follows a positive recommendation from the European Medicines Agency. Biocon's existing US oncology portfolio includes four other biosimilars.

Sentiment
69%
TBN's observations

First-hand measurement across 4 sources

We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 44/100.

Outlets measured: news18, mint, thefinancialexpress, businessstandard. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 4 sources · Published under editorial oversight by The Balanced News
Analysed 16 Nov 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Positive (69/100)

Sentiment was consistent across outlets (62–75/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

businessstandard broke this story on 16 Nov, 04:21 am. Other outlets followed.

16 Nov, 04:21 am4 sources · 2 h16 Nov, 06:03 am
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
Real-Time Stock Updates and Analysis for ICICI Bank and IndusInd Bank
Next →
Aditya Birla Housing Finance Considers IPO and Other Capital-Raising Options to Expand
  1. 1
    businessstandard16 Nov, 04:21 am
    Biocon secures US FDA approval for Pebrilzo, its fifth cancer biosimilar
  2. 2
    thefinancialexpress16 Nov, 05:26 am
    Biocon gets US FDA approval for cancer biosimilar Pebrilzo; launch expected in 2028
  3. 3
    mint16 Nov, 05:58 am
    Biocon gets USFDA nod for breast cancer biosimilar Pebrilzo
  4. 4
    news1816 Nov, 06:03 am
    Biocon gets USFDA nod for breast cancer biosimilar Pebrilzo

Who's involved

Institutions and figures named across source coverage.

Government
United States Food and Drug AdministrationEuropean Medicines Agency Committee for Medicinal Products for Human Use
Corporate
GenentechBiocon Limited

Story context

Category
Business
Location
New Delhi, India
Sources analysed
4
Last analysed
16 Nov 2026
Key entities
HER2PertuzumabBioconBiosimilarOncologyFood and Drug AdministrationMonoclonal antibodyReceptor (biochemistry)CancerCommittee for Medicinal Products for Human UseGenentechEuropean Medicines Agency